The DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index.
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Open accessAbstract
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease that is closely linked both spatially and temporally to emergence of neurodegeneration and manifestation of clinical symptoms. There is an urgent need for accurate PET, CSF, and plasma biomarkers of tau pathology to improve the diagnostic process in clinical practice and the selection of participants and monitoring of treatment effects in trials.Recent developments Innovative second-generation tau-PET tracers with high affinity and selectivity to tau pathology in Alzheimer's disease have enabled detection of tau pathology in medial temporal lobe subregions that are affected in the earliest disease stages. Furthermore, novel but common tau spreading subtypes have been discovered using tau-PET, suggesting much greater interindividual differences in the distribution of tau pathology across the brain than previously assumed. In the CSF biomarker field, novel phosphorylated tau (p-tau) assays have been introduced that better reflect tau tangle load than established CSF biomarkers of tau pathology. The advent of cost-effective and accessible blood-based biomarkers for tau pathophysiology (ie, p-tau181, p-tau217, and p-tau231) might transform the Alzheimer's disease field, as these biomarkers correlate with post-mortem Alzheimer's disease pathology, differentiate Alzheimer's disease from other types of dementia, and predict future progression from normal cognition and mild cognitive impairment to Alzheimer's disease. In controlled investigational settings, improvements in tau-PET and biofluid p-tau markers have led to earlier disease detection, more accurate diagnostic methods, and refinement of prognosis. The anti-tau therapy landscape is rapidly evolving, with multiple ongoing phase 1 and 2 trials of post-translational modification of tau, tau immunotherapy, tau aggregation inhibitors, and targeting production of tau and reduction of intracellular tau levels. Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is crucial to find ways to reduce the need for PET scans due to their relative inaccessibility and costliness, while still preserving the ability to estimate the load and distribution of AD pathology as accurately and comprehensively. 12 , 13”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a major component of NFTs, tau protein exhibits a spatial and temporal distribution that strongly correlates with clinical symptoms, making it a highly specific pathological biomarker in AD patients.152”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Self-citationThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citation
Cited by
Sorted by citations
Items 301–400 of 557
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
Benzinger, T. L. S., Cogswell, P. M., Arani, A., Chaney, A. M., Hutson, K., Glasser, M. F., Graff‐Radford, J., McConathy, J., Raji, C. A., Teunissen, C. E., et al. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(26)00285-1 · Cited by 4
Sharma, A., Feng, L., Muresanu, D. F., Tian, Z. R., Lafuente, J. V., Buzoianu, A. D., Nozari, A., Bryukhovetskiy, I., Manzhulo, I., Wiklund, L., et al. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.05.009 · Cited by 3
Sasidharan, R., Ratheesh, M., Kukreti, N., Raj, P., Abdelgawad, M. A., Ghoneim, M. M., Manju, S. L., & Mathew, B. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04031-6 · Cited by 3
Research progress on humoral biomarkers of Alzheimer’s disease: A review
Zhang, H., Fu, X., Yang, M., Song, X., Li, M., & Wang, X. (2024) · Medicine · doi:10.1097/md.0000000000038978 · Cited by 4
Wu, L., Su, J., Li, G., Zhuang, M., Sun, H., & Zhang, J. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf058 · Cited by 6
Yang, W., Yu, Q., Wang, N., Lam, K. K. Y., Lin, Z., & Xian, Y. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08860-2 · Cited by 4
Potential role of FNDC5 in exercise-induced improvement of cognitive function
Zhao, R., Zhou, X., Wang, D., Tang, H., & Ni, G. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2400016 · Cited by 3
Li, J., Xu, Y., Balboni, G., & Xia, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1587219 · Cited by 3
Hu, X., Lin, Y. W., Huang, K., Xu, H., Fu, C. H., Ou, J., Fan, X., Li, Z., Fang, J., & Fang, S. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00960-x · Cited by 3
Cheng, F., Fransson, L., & Mani, K. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70162 · Cited by 3
Li, Y., Lin, H. T., Liu, K., & Kan, X. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70706 · Cited by 3
Wang, S., Kang, D. W., Um, Y. H., Kim, S., Kim, R. E. Y., Kim, D., Lee, C. U., & Lim, H. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411250 · Cited by 3
Top 100 most-cited articles on tau protein: a bibliometric analysis and evidence mapping
Chen, Z., Shan, G., Wang, X., Zuo, Y., Song, X., Ma, Y., Zhao, X., & Jin, Y. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1345225 · Cited by 3
Kumar, H., Datusalia, A. K., Kumar, A., & Khatik, G. L. (2024) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416524500261 · Cited by 3
Mao, S., Zhao, X., Wang, L., Man, Y., & Li, K. (2025) · European journal of medical research · doi:10.1186/s40001-025-02277-0 · Cited by 3
Surgical advances in the treatment of Alzheimer's disease: A comprehensive review
Xie, F., Ye, Y., Hao, J., Liu, H., Richard, S. A., & Sen, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251364397 · Cited by 3
Differential proteomic profile of lumbar and ventricular cerebrospinal fluidPreprint
Rostgaard, N., Olsen, M. H., Ottenheijm, M. E., Drici, L., Simonsen, A. H., Plomgaard, P., Gredal, H., Poulsen, H. H., Zetterberg, H., Blennow, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2048750/v1 · Cited by 3
Multi-class Modeling Identifies Shared Genetic Risk for Late-onset Epilepsy and Alzheimer’s DiseasePreprint
Fu, M., Tran, T., Eskin, E., Lajonchere, C., Paşaniuc, B., Geschwind, D. H., Vossel, K. A., & Chang, T. S. (2024) · medRxiv · doi:10.1101/2024.02.05.24302353 · Cited by 3
Zyuz’kov, G. N., Miroshnichenko, L. А., Polyakova, T. Y., Simanina, E. V., Chaykovskyi, A. V., Vi, A., & Вадимович, Ж. В. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06258-x · Cited by 3
An, L., Binette, A. P., Hristovska, I., Vilkaite, G., Xiao, Y., Zendehdel, R., Dong, Z., Smets, B., Saloner, R., Tasaki, S., et al. (2025) · medRxiv · doi:10.1101/2025.06.27.25330344 · Cited by 3
Self-citationAlzheimer's Disease : Current Landscape and Future Directions
Kaur, R., Duvey, B. K., Anjali, Vashisht, M., Goel, V., Nidhi, Kumar, V., & Bhargava, A. (2024) · International Journal of Scientific Research in Science and Technology · doi:10.32628/ijsrst24115100 · Cited by 2
Advances in Alzheimer's Disease Biomarkers
Li, K., Gao, Y., Liu, M., & Chen, Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050366767241223050957 · Cited by 3
Li, B., Li, H., Chen, H., Sui, Y., Zeng, J., Lin, X., Fan, Q., & Song, Z. (2025) · Physiological Research · doi:10.33549/physiolres.935447 · Cited by 2
Asif, M., Ullah, H., Jamil, N., Riaz, M., Zain, M., Pushparaj, P. N., & Rasool, M. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273374284250519053646 · Cited by 2
Wu, Y., Zhan, Y., Zhu, W., & Pei, J. (2025) · Medicine · doi:10.1097/md.0000000000042651 · Cited by 2
Is screening for Alzheimer’s disease ready for prime time? Ask Wilson and Jungner
Chatanaka, M. K., Loren, M., & Diamandis, E. P. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2533860 · Cited by 2
Abbate, C., & Gallucci, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251374319 · Cited by 2
Chu, X., Guo, Y., Fu, Y., Ren, H., Wang, H., Shen, C., Song, R., Zeng, Q., Ibrahim, F. E. E. M., Li, Y., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70234 · Cited by 3
Hellquist, E., Janelidze, S., Weidung, B., Franzon, K., Giedraitis, V., Ingelsson, M., Bali, D., Veličkaitė, V., Zetterberg, H., Hansson, O., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251390387 · Cited by 2
Self-citationChen, C., Chen, Q., Zou, H., Zhao, C., & Wang, X. (2025) · International Dental Journal · doi:10.1016/j.identj.2025.109327 · Cited by 2
Pérez‐Ruixo, C., Li, L., Galpern, W. R., & Ruixo, J. J. P. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70173 · Cited by 2
Li, R., Wu, X., Yao, J., Chen, J., Shui, X., Zheng, X., Tian, W., Wang, L., Zhou, Y., Zhang, T., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.12.037 · Cited by 2
Cerebrospinal fluid markers of alzheimer’s pathology relate to aMCI among people with HIV
Lobo, J. D., Serrano, V. B., Campbell, L. M., Bell, T., Gouaux, B. D., Galasko, D. R., Letendre, S. L., Bondi, M. W., Moore, D. J., & Sundermann, E. E. (2026) · BMC Neurology · doi:10.1186/s12883-025-04585-8 · Cited by 2
Zhang, Y., An, Y., Yang, M., Huang, Y., Yu, S., Xu, X., & Yang, C. J. (2026) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2026.139727 · Cited by 3
Tatar, A.-S., Colniță, A., Brezeștean, I.-A., & Boca, S. (2026) · Biophysical Reviews · doi:10.1007/s12551-026-01428-9 · Cited by 2
Fang, M., Yan, Y., Song, W., Geng, Z., Wang, L., Hu, C., Li, W., Song, B., Chen, M., Dai, Y., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02033-4 · Cited by 2
The mechanisms and strategies for Alzheimer’s disease prevention: An update
Han, M., Wang, N., Song, M., Liu, C., Wu, Y., Yin, J., Jin, L., Jin, W., & Gao, Z. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.007 · Cited by 3
He, Y., 杜雨柔, Liu, D., Che, P., Wang, Y., Li, J., Wang, C., & Zhang, N. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04043-0 · Cited by 2
Gerwert, G., Mann, M., Langenhoff, L., Woitzik, N., Hubert, D., Duman, D., Höveler, A., Budde, S., Simon, J., Beyer, L., et al. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c00433 · Cited by 2
Khasanov, S. K., Tolibov, M., & Daminova, N. K. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121046 · Cited by 3
Zafari, R., Kamroo, A., Taherkhani, T., Nabizdeh, F., & Aarabi, M. H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.05.010 · Cited by 3
小山, 幸., Pham, L., Murakawa, Y., Ogawa, Y., 寺内加奈子, & Davis, K. (2026) · Plants · doi:10.3390/plants15111619 · Cited by 2
Hu, P., Guo, S., Ren, Y., Zhao, R., Su, L., Cheng, J., & Tian, X. (2026) · ACS Sensors · doi:10.1021/acssensors.6c01055 · Cited by 2
Hasan, M., Abd-Elraouf, K., Moran, S. R., & Lo, C. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125467 · Cited by 2
Feng, Q., Song, Y., Pan, Z., Liu, W., Xu, H., Wang, L., Cheng, H., Wang, P., & Chen, G. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.119004 · Cited by 2
Abdelaziz, A. M., & Eltyar, F. S. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110777 · Cited by 2
Torraville, S. E., Flynn, C. M., Kendall, T. L., & Yuan, Q. (2023) · Biomedicines · doi:10.3390/biomedicines11071884 · Cited by 4
Sharma, A., Feng, L., Muresanu, D. F., Tian, Z. R., Lafuente, J. V., Buzoianu, A. D., Nozari, A., Wiklund, L., & Sharma, H. S. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.05.011 · Cited by 2
Mestizo-Gutiérrez, S. L., Acosta‐Mesa, H., García-Ortega, F., & Jiménez-Cataño, M. E. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-51940-6_33 · Cited by 2
Huang, T., Gong, X., Liang, Z., Yang, R., Wu, L., Yang, C., Wu, M., Wang, X., Shu, X., & Bao, J. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167197 · Cited by 2
Nguyen, H. D., Vu, G. H., & Kim, W. (2024) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2024.100045 · Cited by 2
Informational Analysis and Prediction of Obsessive-Compulsive Disorder Pathogenesis
Wang, Y., Wang, Y., Zhang, M., Liu, D., & Fang, J. (2024) · Psychiatry Investigation · doi:10.30773/pi.2023.0149 · Cited by 2
Li, T., Liu, R., He, Y., Zhang, B., RUI, X., Yang, X., Wang, J., Zeng, J., Li, G., Li, X., et al. (2024) · Aging Cell · doi:10.1111/acel.14404 · Cited by 2
Listerin Alleviates Alzheimer's Disease through IRE1‐mediated Decay of TLR4 mRNA
Qin, F., Cao, R., Bai, X., Yuan, J., Sun, W., Zheng, Y., Qi, X., Zhao, W., Liu, B., & Gao, C. (2025) · Advanced Science · doi:10.1002/advs.202414956 · Cited by 2
Liu, C., Wang, X., Xu, W., Yu, S., Zhang, Y., Xu, Q., & Tan, X. (2025) · Pharmaceuticals · doi:10.3390/ph18070977 · Cited by 2
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: A Canadian prospective
Kumar, P., Mousavi, A., & Frykman, H. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110980 · Cited by 2
Liang, J., Wang, Y., Liu, B., Dong, X., Cai, W., Zhang, N., & Zhang, H. (2023) · doi:10.22541/au.169753470.03178440/v1 · Cited by 2
Fei, Z., Pei, R., Pan, B., Ye, S., Zhang, R., Ma, L., Wang, Z., Li, C., Du, X., & Cao, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065549 · Cited by 1
Constructing a prognostic risk model for Alzheimer’s disease based on ferroptosis
Wang, X., Zhai, R.-Q., Li, Z., Li, H.-Q., Lei, Y.-T., Zhao, F.-F., Hao, X.-X., Wang, S., & Wu, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1168840 · Cited by 1
Cognitive impairment and dementia
Sunde, A. L., & Aarsland, D. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.23.0407 · Cited by 1
Treatment of Alzheimer’s disease based on new drugs
Jia, J., Yuan, Y., & Zhang, Z. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/20/20230703 · Cited by 1
Chen, A., Shea, D. W., & Daggett, V. (2024) · Scientific Reports · doi:10.1038/s41598-024-57107-w · Cited by 1
Associations of Serum Isoleucine with Mild Cognitive Impairment and Alzheimer’s Disease
Jing, X.-J., Zan, Z.-Y., Zhou, X., Xiong, Y.-L., Ren, S.-J., Zhang, H., & Initiative, T. A. D. N. (2024) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.23.0216 · Cited by 1
Kumar, H., Datusalia, A. K., Kumar, A., & Khatik, G. L. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249319554240930050002 · Cited by 1
Introduction to Alzheimer's Disease and Biomarkers
Gupta, K. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-6442-0.ch004 · Cited by 1
López, S. F., Ferrero, R., Blom-Dahl, J., Alonso-Bernáldez, M., González, A. S. T., Pérez-Solero, G., & Tenorio, J. A. (2025) · Genes · doi:10.3390/genes16040377 · Cited by 1
New biomarkers for early-stage tau pathology in Alzheimer’s disease
Luo, R., & Yu, J. (2025) · Nature Aging · doi:10.1038/s43587-025-00854-w · Cited by 1
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Zhan, Y., Zuo, F., Zhang, Z., Wu, X., Dai, Y., Jiao, T., Shi, Q., Wang, Z., & Zhang, G. (2025) · Journal of Visualized Experiments · doi:10.3791/67574 · Cited by 1
Chen, K., Yao, X., Yu, Y., Sun, J., Zhang, Y., Ma, H., Zheng, H., Qiu, B., Li, H., Zhao, W., et al. (2025) · Journal of Applied Toxicology · doi:10.1002/jat.4791 · Cited by 1
Pa, C., Shen, S., Dai, Y. L., & Wu, M. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1614132 · Cited by 2
Tau Pathology in Alzheimer's Disease: Bridging Molecular Mechanisms and Targeted Therapies
Dahiya, M., Yadav, M., Kumar, A., & Goyal, C. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273376581250626003322 · Cited by 2
Huang, X., Xu, Z., Fu, F., Song, J., Zeng, J., Huang, S., & Yue, F. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110849 · Cited by 1
Testosterone as a mediator of APOE4-linked sex differences in Alzheimer's disease
Shi, Z., Wu, L., Zhang, C., Zeng, X., Yao, G., He, X., Hu, J., Xie, T., & He, L. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115588 · Cited by 3
Zinc homeostasis imbalance: Potential therapeutic value in neurodegenerative diseases
Zhang, Z., Deng, W., Hu, L., Hu, Y., Zhang, S., Xiong, Y., Liu, X., Yu, P., Yu, S., Yuan, L., et al. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00632 · Cited by 2
Wang, X., Shen, Y., Lei, C., Chai, J., Tan, Q., & Qin, Y. (2025) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000549394 · Cited by 1
Li, Z., Liu, X., & Zeng, H. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5701 · Cited by 2
Exploring the skin as an open window onto neurodegenerative diseases
Lozzi, F., Camera, E., Cardinali, G., & Nardo, A. D. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00522-4 · Cited by 3
Cell-based immunotherapy for neurodegenerative disease: A promising avenue
Huerta, T. J., Urbina-Muñoz, V., Urra-Alvarez, V., Villablanca, C., Gómez‐Pérez, L. S., Saavedra, B., Contreras, T., & Vidal, R. L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00816 · Cited by 1
Exercise mitigates Alzheimer’s disease by targeting ferroptosis driven by cellular senescence
Yu, Y., & Chen, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1742209 · Cited by 4
Hsieh, P.-H., Chen, Y.-F., Ta-Fu, C., & Wu, W. (2026) · European Journal of Radiology · doi:10.1016/j.ejrad.2026.112678 · Cited by 1
Alzheimer’s Disease Pathologies Affect Dopaminergic Neural Mechanisms of Memory
Morin, T., Cowan, J. L., Chen, H.-Y., Parent, J. H., Crawford, J. L., Ciampa, C. J., Shah, V. D., Hsu, M. H., Jagust, W. J., & Berry, A. S. (2026) · Journal of Neuroscience · doi:10.1523/jneurosci.1580-25.2026 · Cited by 2
Unmasking the hidden catalyst: How infections trigger Alzheimer's disease
Fülöp, T., Cohen, A. A., Frost, E. H., Lévesque, S., Khalil, A., Rodrigues, S., Desroches, M., Alami, M., Berrougui, H., Ramassamy, C., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251415571 · Cited by 2
Fernandes, M. G. F., Pinard, M., Sokullu, E., Tremblay, C., Gagnon, J., Calon, F., Coulombe, B., & Brouillette, J. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag009 · Cited by 1
Li, B., Liu, C., Gu, C., Wei, S., Li, S., Liu, Z., Zhao, D., Tang, Q., Chen, Y., & Chen, Z. (2026) · Biosensors · doi:10.3390/bios16020113 · Cited by 1
The role of GDNF in neurodegenerative pathologies
Kolesnikova, A., Ushakova, V. M., Zorkina, Y., Andriushchenko, A., Zubkov, E. A., Chekhonin, V. P., & Kostyuk, G. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00234-z · Cited by 1
Emanuel, O. M., Miner, A. E., Lee, S. Y., Matusz, E. F., Tanner, J. J., Marsiske, M., Holgerson, A. A., Ly, M. T., Tuz‐Zahra, F., Tripodis, Y., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214646 · Cited by 1
Rogacz, Z., Pacuła, W., Strzałka‐Mrozik, B., & Turek, A. (2026) · Applied Sciences · doi:10.3390/app16052554 · Cited by 2
Guo, G., Song, W., Wang, A., Cui, Q., Yang, X., Wang, Y., Ma, Y., Han, H., Li, Z., Zhang, Z., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-44192-2 · Cited by 1
Cao, K., Xie, J., Liang, X., Li, Y., Gong, H., & Luo, H. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00917 · Cited by 2
Setiawan, A. W., Choi, J. T., Park, S., Choi, M., Tjandrawinata, R. R., Hadinata, E., Park, M. N., Ikrar, T., Nurkolis, F., & Kim, B. (2026) · Pharmaceuticals · doi:10.3390/ph19050792 · Cited by 1
Wang, L., Su, Y., Niu, J., Liu, Y., & Hou, X. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118911 · Cited by 1
Using gut neuron health as a predictive indicator of neurodegenerative disease
Langerová, T., & Gregory, J. M. (2026) · Future Neurology · doi:10.1080/14796708.2026.2684938 · Cited by 1
Sun, Z., Shen, T., Li, M., Li, Z., & Zhang, J. (2026) · Sleep And Breathing · doi:10.1007/s11325-026-03671-6 · Cited by 1
Macías, E. F., Noval-Padillo, J. Á., Hervás-Navidad, R., Espejo-Martínez, B., Serrano-Gutiérrez, C., Rodrigo‐Herrero, S., Méndez-Barrio, C., Mendoza-Vázquez, G., Carrera-Muñoz, I., Marín-Romero, B., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261459067 · Cited by 1
Li, D., Zhang, Z., Lei, L. U., Liu, J., Cai, W., Hou, J., Lu, Y., & Yu, G. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112689 · Cited by 4
Salman, Y., Denning, A. E., Schaeverbeke, J. M., Tomé, S. O., Joudiou, N., Khandelwal, P., Yushkevich, P. A., Vandenberghe, R. R., Gallez, B., Wisse, L. E. M., et al. (2026) · NeuroImage · doi:10.1016/j.neuroimage.2026.122098 · Cited by 1
Morsy, N., El‐Shiekh, R. A., Ebrahium, M. M., & Srour, A. M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110245 · Cited by 1
Trares, K., Duman, D., Beyer, L., Michaelian, J. C., Stocker, H., Holleczek, B., Beyreuther, K., Schöttker, B., Gerwert, K. B., & Brenner, H. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00483-9 · Cited by 1
Liu, L., Chen, X. J., Zeng, Q., Zhou, S., & Zhang, X. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1899123 · Cited by 1
Yang, J., Zhao, X., Liu, Y., Cai, Y., Fan, Y., & Initiative, A. T. A. D. N. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.050676 · Cited by 1
Metadata
- Authors
- Ossenkoppele, R., van der Kant, R., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Ossenkoppele, Rik
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 21
- Issue
- 8
- Pages
- 726-734
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4281564421
- Cited by
- 557
- References
- 79
- Citations by year
- 2026: 127 · 2025: 174 · 2024: 142 · 2023: 98 · 2022: 15
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau pathology, tau biomarkers, tau PET tracers, phosphorylated tau, cerebrospinal fluid biomarkers, blood-based biomarkers, anti-tau therapy, clinical trial participant selection, early disease detection, tau immunotherapy, tau aggregation inhibitors, dementia diagnosis, mild cognitive impairment, primary care
- MeSH terms
- Alzheimer Disease, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neuroimaging, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
